Testing the Addition of an Immunotherapy Drug, Cemiplimab (REGN2810), Plus Surgery to the Usual Surgery Alone for Treating Advanced Skin Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Sun Yat-sen University
Merus B.V.
National Cancer Institute (NCI)
First Affiliated Hospital of Guangxi Medical University
AstraZeneca
Johnson & Johnson Enterprise Innovation Inc.
Merck Sharp & Dohme LLC
Janssen Research & Development, LLC
Canadian Cancer Trials Group
Gustave Roussy, Cancer Campus, Grand Paris
Sun Yat-sen University
All India Institute of Medical Sciences
Hoffmann-La Roche
Eastern Cooperative Oncology Group
Alliance for Clinical Trials in Oncology
Affiliated Hospital of Guangdong Medical University
National Cancer Institute (NCI)
Centre Francois Baclesse
Eastern Cooperative Oncology Group
Universität des Saarlandes
NRG Oncology
Eastern Cooperative Oncology Group
Fudan University
Fudan University
R-Pharm
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
M.D. Anderson Cancer Center
Merus B.V.
EMD Serono
University of California, Davis
Sun Yat-sen University
Sun Yat-sen University
Merck Sharp & Dohme LLC
Sun Yat-sen University
European Organisation for Research and Treatment of Cancer - EORTC
Sun Yat-sen University
Sun Yat-sen University
Shanghai Miracogen Inc.
Shandong Cancer Hospital and Institute
Canadian Cancer Trials Group
Radiation Therapy Oncology Group
Boehringer Ingelheim
Shandong Cancer Hospital and Institute
Sun Yat-sen University
Sun Yat-sen University
West China Hospital
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.